“…Additionally, 17-N-Allylamino-17-demethoxygeldanamycin (17-AAG); retaspimycin hydrochloride (IPI-504), two Hsp90 inhibitors, provided no benefit to CRPC patients (55,56). The poor therapeutic effect of Hsp90 inhibitors may be the consequence of inhibiting widespread client proteins and may thereby result in activation of oncogenic signaling pathways such as Src and co-chaperone Hsp27 up-regulation (57,58). Inhibition of Cdc37, a co-chaperone of Hsp90 that is overexpressed in cancer cells, may represent a better drug target in cancers (59).…”